It can be envisaged that NLRC5-deficient clones arising during cancer progression, lacking both MHC-Ia and MHC-Ib, would impair conventional and unconventional CD8+ T cell activation towards these clones but would favor NK cell activation. The gene discussed is CD8A; the disease is cancer.